Cottonwood Management, LLC

PwC in Boston, MA is a global professional services firm that offers a wide range of capabilities including audit and assurance, consulting, cybersecurity, deals, digital transformation, sustainability, and tax services. They serve various industries such as consumer markets, energy, financial services, health, industrial products, and technology, providing expertise and solutions to help clients navigate complex business challenges. With a focus on digital trust and innovation, PwC leverages advanced technologies and strategic insights to help organizations transform and thrive in an ever-evolving business landscape. Their team of experienced professionals, combined with their extensive global network, enables them to deliver tailored solutions and drive value for their clients.Generated from the website

Steelcase Inc. is a global leader in office furniture and interior architecture, providing innovative space solutions for various environments including offices, hospitals, and classrooms. The company's offerings are informed by extensive research in workspace design, ensuring that their products meet the evolving needs of users. With a commitment to enhancing community through inclusive design, Steelcase aims to create spaces that foster a sense of belonging for diverse individuals. Their extensive range of products includes seating, privacy solutions, and ancillary collections, all designed to support productivity and collaboration in modern workspaces. Generated from the website

Alexion Pharmaceuticals is engaged in the discovery and development of therapeutic products aimed at treating patients with an array of diseases, including hematologic and cardiovascular disorders, autoimmune diseases and cancer. Alexion's two primary product candidates, pexelizumab and eculizumab, are currently undergoing evaluation in several clinical development programs with the Federal Drug Administration. Alexion is engaged in discovering and developing a pipeline of additional antibody therapeutics targeting severe unmet medical needs, through its wholly owned subsidiary, Alexion Antibody Technologies. During the fiscal year ended July 31, 2005, eculizumab was in Phase III clinical development for treatment of paroxysmal nocturnal hemoglobinuria , a chronic hematologic disease, and pexelizumab was in clinical development for two acute cardiac indications. Alexion is also pursuing additional potential indications for eculizumab and has other product candidates in earlier stages of development. Alexion Pharmaceuticals is based in Cheshire, Conn.